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ABSTRACT 
 
 
Efficacy of Oral Altrenogest for Postponing Ovulation in the Mare. 
 
(August 2003) 
      Sandra Lee Murrell, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Martha M. Vogelsang 
 
 
The horse industry relies heavily on the breeding manager’s ability to get 
a large number of mares bred each season.  Therefore, it is beneficial to 
optimize use of the stallion and number of cycles per conception, both of which 
are related to the time of ovulation.  Currently, methods exist to induce ovulation 
of a Graafian follicle; however there is no widely accepted method for delaying 
ovulation.  Considering the main factors that lead to ovulation it could be 
hypothesized that the short-term administration of a progestin, such as 
altrenogest, would have the potential to postpone ovulation of a follicle that has 
reached ovulatory size.  Twenty-six mares ranging in age from three to 23 years 
were paired by age and randomly assigned to a 2X4 blocked experiment.  The 
factors were 1) stallion (Groups A-D) and 2) hormonal treatment (.044mg/kg BW 
altrenogest for 2 d) or control (Neobee M5 oil for 2 d).  Hormonal administration 
for each mare was initiated upon detection of a follicle with a 35 mm or greater 
diameter.  Mares were artificially inseminated starting on the first day of 
treatment and continuing every other day until ovulation was confirmed by 
ultrasonography.  Blood samples were collected daily throughout the estrous 
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cycle and at 12 h intervals from the detection of a 35 mm follicle until three days 
post-ovulation.  Samples were analyzed for luteinizing hormone using a double 
antibody RIA, for progesterone and estradiol using RIA kits (Coat-A-Count® and 
double antibody, DPC®). 
Short-term altrenogest administration increased the number of days to 
ovulation (P<0.05).  Mean days to ovulation from d 1 of treatment for the control 
versus treated mares were 3.15 d and 6.12 d, respectively.  There was no 
difference (P=0.65) between control and treated groups with respect to size of 
follicle at the time of ovulation.  Luteinizing hormone, progesterone and estradiol 
concentrations were analyzed during treatment until 3 d post-ovulation.  
Altrenogest treatment had no effect on LH, progesterone and estradiol 
concentrations as demonstrated by the lack of difference between control and 
treated mares (P=0.27, P=0.56, P=0.67).  There was no difference in pregnancy 
rates (P=0.62) between the control 10/13 and treated 11/13 mares. 
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CHAPTER I 
 
INTRODUCTION 
 
 
 Management of the mare's estrous cycle, especially during the breeding 
season, is a major requirement for a breeding operation.  Manipulation of estrus 
and time of ovulation are primary factors involved in controlling the cycle and 
play a key role in the success of a breeding program.  Unlike other domestic 
species, mares have a long follicular phase that makes artificial control of estrus 
more difficult.  Reasons for controlling time of ovulation are: a) space the 
breeding of a group of animals over a period of time to increase labor and 
management efficiency; b) breed a group of animals within a small window of 
time due to show schedules of either the mares or the stallion; c) schedule 
breeding of individual mares at predetermined times to help owners with board 
fees or for shipped semen; and d) synchronize donor and recipient mares in an 
embryo transfer program.   
The use of artificial insemination (AI) enables the breeder to improve 
breeding management by optimizing use of the stallion, using a minimal number 
of breedings and decreasing the number of cycles per conception in some 
mares. The introduction of sperm into the female tract by AI must precede 
ovulation.  Successful application of AI requires the ability to judge when 
ovulation will occur.  If ovulation can be controlled, handling of mares is made 
_______________ 
This thesis follows the style of the Journal of Animal Science. 
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easier by having to breed a mare only once.  For these reasons, it would be 
beneficial to be able to postpone as well as induce ovulation of a mature follicle.  
Currently, several methods exist to induce rupture of follicle:  an injection of 
human chorionic gonadotropin; GnRH analogue (Buserelin) or agonist 
(Gonadorelin) given as an implant or an injection (Ovuplant®, Deslorelin); or an 
injection of prostaglandin analogue (Fenprostelene). However, there is no 
regimen to delay ovulation of a mature follicle by a couple of days. 
Ovulation occurs as a result of exposing a preovulatory follicle to high 
levels of luteinizing hormone (LH).  At the beginning of the follicular phase, LH 
secretion increases due to the combined effects of estradiol-17β and 
progesterone on the hypothalamic-pituitary-gonadal axis.  Positive feedback of 
estradiol-17β from the growing follicle on the hypothalamus increases GnRH 
secretion.  Decline in the negative feedback of progesterone secretion from the 
corpus luteum on the hypothalamus further allows GnRH secretion to increase.  
Increasing GnRH secretion signals the adenohypophysis to switch from follicle 
stimulating hormone (FSH) secretion to LH secretion.   Conversely, at the 
beginning of the luteal phase, LH secretion decreases due to a switch in the 
above mentioned feedback mechanisms.  Estradiol levels peak and drop before 
ovulation, these low levels no longer provide positive feedback on the 
hypothalamus.  After rupture of the follicle, progesterone production increases 
from the newly formed corpus luteum.  Therefore, it would be reasonable to 
propose that since progesterone has a negative feedback on LH secretion, an 
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exogenous progestagen could delay the interval between selection of a 
predominant follicle and ovulation.   
There is a commercially available oral synthetic progestin, altrenogest 
(Regumate®), developed and approved for use in controlling the estrous cycle in 
the mare.  Long term altrenogest administration (10 to 15 days) has been shown 
to suppress estrus and ovulation by prolonging the luteal phase (Daels et al., 
1996).  However, limited studies are available regarding the effects of short-term 
altrenogest administration late in the follicular phase. 
Objective 
The objective of this study is to validate and define the ability of 
altrenogest administration during estrus to postpone ovulation of a mature follicle 
in the mare.  The hypothesis to be tested is that mares given altrenogest will 
demonstrate a delay in ovulation versus controls.  The expected results are that 
altrenogest treated mares will demonstrate a longer interval to ovulation, have 
lower LH concentrations and no difference in either progesterone or estradiol 
concentrations versus control mares.  Additionally, pregnancy rates for treated 
versus control mares will be evaluated to provide credibility for the treatment 
regimen. 
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CHAPTER II 
LITERATURE REVIEW 
 
Dynamics of the Estrous Cycle 
 Follicular phase.   The follicular phase, also known as estrus, varies in 
length from four to seven days in the mare (Blanchard et al., 1998).  Estrus is 
accompanied by follicular growth, selection, maturation and then ovulation.  
Follicular growth results from a surge in follicle stimulating hormone (FSH) 
release from the adenohypophysis.  Selection of a dominant follicle is due to 
decreasing levels of FSH and increasing levels of luteinizing hormone (LH) from 
the adenohypophysis (Samper, 2000).  Systemic levels of FSH decrease while 
LH increases due to increasing estrogen production from the growing follicles.  
Final maturation of the follicle is accomplished by a switch in gonadotropin 
dependency of the mature follicle from FSH to LH.   There is a marked decrease 
in the number of FSH receptors on the granulosa cells along with acquisition of 
LH receptors (Samper, 2000).  Ovulation occurs approximately 48 hours before 
the end of estrus in mares (Ginther, 1992; Mckinnon and Voss, 1993).  The high 
concentration of LH or LH surge results in rupture of the follicle (ovulation).  
 Luteal phase.  The luteal phase, also known as diestrus, accounts for the 
remainder of the estrous cycle.  It is usually about 14 to 15 d in length, 
depending on the length of estrus which is more variable (Blanchard et al., 
1998).   Diestrus starts after ovulation by formation of the progesterone secreting 
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corpus luteum (CL).  There is change of the follicular granulosa cells into luteal 
cells.  Ovulation results in marked decrease of estrogen production.  The 
combination of decreasing estrogen production and the increasing progesterone 
production leads to the decline in LH levels (Samper, 2000).  
 
 
 
 
Figure 1.  Schematic representation of the hormonal pathway of the 
hypothalamic-hypophyseal-gonadal axis during the estrous cycle.  Solid lines 
indicate positive feedback.  Dashed lines indicate negative feedback. 
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Hormonal Events of Ovulation 
Luteinizing hormone.  Ovulation occurs during the follicular phase of the 
estrous cycle and is the result of a cascade of events that is initiated by a surge 
of LH.  The gonadotropin, LH, is necessary for final follicular growth, ovulation 
and formation of the corpus luteum (CL) (Guyton and Hall, 1996).  The source of 
LH is gonadotroph cells of the adenohypophysis.  The peptide hormone, GnRH, 
controls the circhoral (hourly) pattern of LH secretion from the adenohypophysis.  
GnRH is synthesized and released by neurosecretory cells located in the 
median eminence of the hypothalamus (Ginther, 1992) and reaches the 
adenohypophysis by the hypothalamic-hypophyseal portal system (refer to 
Figure 1).  Episodic secretion along with fluctuations in frequency and amplitude 
of GnRH secretion are important in generating the hormonal changes during the 
cycle (Guyton and Hall, 1996).  More frequent pulses late in the follicular phase 
lead to the LH surge (Turner and Irvine, 1991).  Gonadotropin patterns of the 
mare are considerably different compared with other mammals.  Most mammals 
exhibit a short-lived surge of gonadotropins 12 to 24 hours prior to ovulation; 
however, the mare has a prolonged rise and decline of LH which occurs over a 
period of about 10 days (Ginther, 1992).  During mid-diestrus, mean LH values 
in mares are low and remain low until beginning to rise a few days before the 
onset of estrus.   Luteinizing hormone concentrations increase progressively 
after the onset of estrus to peak one to two days after ovulation (Ginther, 1992; 
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Irvine and Alexander, 1997).  Concentrations then decrease progressively over 
the next four to six days to return to low diestrous values (Ginther, 1992). 
Estradiol.  LH secretion is regulated by complex interactions among 
gonadal steroid hormone secretions, neuromodulators and neurotransmitters 
(Alexander et al., 1995).  The ovarian hormone, estrogen (E), is responsible for 
behavioral estrus in mares and facilitates the LH surge (Ginther, 1992).  It has 
the preeminent role of setting the neural trigger for the preovulatory 
gonadotropin surge (Mahesh and Brann, 1992).  Estradiol is known for inducing 
an ovulatory-like surge of LH in females of numerous species (Alexander et al., 
1995).  Secretion of estradiol-17β, the primary estrogen produced, occurs from 
the granulosa cells of maturing, or Graafian, follicles.  There is a steady increase 
of estradiol-17β, at the onset of estrus, with its peak occurring 12 to 27 h prior to 
ovulation (Ginther, 1992).  Estradiol modulates LH by a long feedback loop to 
the hypothalamus and pituitary (Mahesh and Brann, 1992).  Increasing estradiol-
17β concentration has two modes of action for increasing LH secretions that will 
lead to ovulation.  First, there is a direct increase in pulsatile secretions of GnRH 
from the hypothalamus.  The second mode is by increasing the sensitivity of the 
anterior pituitary cells to GnRH by increasing the number of receptors located on 
the gonadotropes (Knobil and Neill, 1999).  One possible way to postpone 
ovulation, therefore, could be to suppress estradiol-17β.  However, the 
physiological actions of estrogen are exhibition of behavioral estrus, relaxation of 
the cervix, increased diameter of the cervical canal, increased secretion of 
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oviductal fluid and increased production of fluid with high lubricating properties 
from both the cervix and vagina (Knobil and Neill, 1999).  All of these are 
required for preparing the right environment for the sperm and ovum before 
fertilization and for early embryo development (Ginther, 1992). 
 Progesterone.  The ovarian hormone, progesterone (P), is considered the 
hormone of pregnancy because its presence results in quiescence of the smooth 
muscle of the uterus and prevents behavioral and physiologic signs of estrus. 
The CL secretes P during the luteal phase of the estrous cycle resulting in the 
diestrus between consecutive ovulations.  Progesterone exerts a powerful 
negative feedback on the release of LH (Garcia et al., 1979; Allen et al., 1980) 
from the pituitary and hypothalamus.  Luteinizing hormone concentrations do not 
start to rise until after regression of the CL (Garcia and Ginther, 1978; Evans, 
1982).  Sharp and Grubaugh (1987) showed that the hypothalamic release of 
GnRH is slowed at the end of estrus during the time that P is increasing.  
Progesterone decreases the pulse frequency of GnRH, thereby decreasing the 
signal for the release of LH (Karsch, 1987).  Progesterone concentrations during 
estrus are < 2ng/ml and do not have a negative control over LH, thus allowing 
the cascade of hormones leading to the ovulatory surge of LH.  Progesterone, in 
the mare, alone does not activate tonic opioid inhibition of LH but modulates the 
effect of estrogens (Aurich et al., 1995).  Progesterone receptors on granulosa 
cells of several species (Schreiber and Erickson, 1979; Jacobs and Smith, 1980; 
and Jacobs et al., 1980) are important in that they allow P to augment the ability 
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of FSH to stimulate pregnenolone synthesis.  Pregnenolone is used to create P 
instead of allowing the cholesterol to be converted into estrogens (Fanjul et al., 
1983).  At the level of the granulosa cell, P also provides a negative feedback on 
the aromatization of androgens to estradiol-17β.  The administration of P always 
suppresses estradiol and its feedback (Knobil and Neill, 1999).  Therefore, the 
administration of a progestin during estrus could have the potential to halt the 
growth, maturation and eventual ovulation of a follicle. 
Hypothalamus 
 The hypothalamus is medially located and the most ventral portion of the 
third ventricle.  It forms the lower parts of the lateral walls of the third ventricle.  
Its anterior boundary is the optic chiasm.  Its posterior boundary is defined by 
the mammillary bodies.  It is separated from the temporal lobes, laterally, by the 
hypothalamic sulci.  The base of the hypothalamus is the tuber cinereum.  The 
median eminence is the central part of the tuber cinereum.     
Regulation of GnRH secretion.  There is a complex interplay of 
neurotransmitters and the neurons that secrete GnRH.  The gonadal steroids (E 
and P) are the primary regulators of GnRH secretion.  Since the GnRH neurons 
do not possess steroid receptors, the gonadal steroids must act through other 
neurons which do contain steroid receptors.  The presence of monoamine, 
peptide or amino acid-containing afferent fibers has been documented on GnRH 
neurons, mainly in rodents and sheep (Caldani et al., 1993).   Afferent fibers 
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conduct inward and so those neurotransmitter afferents would be going toward 
the GnRH neurons. 
The involved monoamines are catecholamines (dopamine and 
noradrenaline) and indolamine (serotonin).  Noradrenaline suppresses the LH 
pulses in ovariectomized rats.  In contrast, noradrenaline triggers LH secretion 
when injected into estradiol-treated ovariectomized rats.  And, noradrenaline is 
involved in the mechanism which triggers the preovulatory surge of LH in 
conjunction with adrenaline (Knobil and Neil, 1999).   
Dopamine inhibits the pulsatile release of LH in ovariectomized rats.  It 
also contributes to the negative feedback of estradiol and therefore is believed to 
play a role in prepubertal animals.  The stimulatory and inhibitory roles of 
dopamine have not been attributed to any specific parts of the brain (Caldani et 
al., 1993). 
Serotonin induces inhibition of both the pulsatile and preovulatory release 
of LH.  It also has stimulatory effects associated with the time of the preovulatory 
surge.  During the anestrus period, in the ewe, serotonin is involved in the 
steroid independent-inhibition of the LH pulsatile release (Barraclough and Wise, 
1982).   In summary, the monoamines interact with steroids to alter GnRH 
secretion. 
Various neuropeptides are able to alter GnRH secretion.  Among them 
are opiates, β-endorphins and enkephalins.  Of the aforementioned, opiates are 
probably the most important.  Endogenous opioid peptides (EOPs) modulate LH 
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release by suppressing the GnRH pulse generator either in the hypothalamus 
and/or brain in several species (Behrens et al., 1993).  Alterations in the steroid 
environment and stage of estrous cycle strongly influence the regulation of LH 
secretion by EOPs (Nanda et al., 1991).  In the mare, evidence exists that EOPs 
are involved in the regulation of LH release.  Opioids inhibit LH release in 
anovulatory mares during the non-breeding season and in cyclic mares during 
the luteal phase of the cycle (Aurich et al., 1995).  Behrens et al. (1993) showed 
that naloxone, an opioid antagonist, did not lead to an increase in LH 
concentrations during the follicular phase in mares.  Since opioids do not 
contribute to follicular phase dynamics they do not warrant consideration as a 
means of postponing ovulation. 
The amino acid, gamma aminobutyric acid (GABA) is involved in many 
forms of inhibition in the central nervous system.  GABA increases the interval 
between pulses of LH in rats, rabbits and sheep (Caldani et al., 1993).  These 
different kinds of neurons can modulate physiology of the GnRH neurons directly 
or after integration of hormonal information has been received from the ovaries.  
As was previously mentioned, most of these afferents come from neurons which 
have the property to bind sexual steroids.  So they also act through the steroids 
to alter the secretion of GnRH.    
Adenohypophysis 
 The adenohypophysis (anterior pituitary) is suspended below the 
hypothalamus by the infundibulum and lies in a recess on the floor of the 
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cranium called the sella turcica.  It is connected to the hypothalamus by the 
pituitary stalk, which arises from the median eminence (a midline, ventral 
projection from the tuber cinereum) and together they interact to direct the 
secretion of many different hormones.  The adenohypophysis and the 
hypothalamus share a direct path of communication, the hypothalamic-
hypophyseal portal system.  This portal system directs the neurotransmitters 
released in the hypothalamus to the target cells of the adenohypophysis to 
mediate the release of specific hormones.   
 Gonadotropes.  Gonadotropes are the target cells of the neurotransmitter 
GnRH.  Gonadotropes are mainly localized within the pars distalis and pars 
tuberalis of the adenohypophysis.  Kurosumi and Inoue (1986) described 
gonadotropes as follows: they contain large amounts of rough endoplasmic 
reticulum (RER) for their glycoprotein-producing role; they are considered 
granulated adenohypophyseal cells and contain a large number of Golgi 
apparati.  The Golgi apparatus (GERL) is located in the juxtanuclear region near 
the center of the cell.  The GERL consists of flattened membranous sacs 
(cisternae).  There is a polarity associated with the poles of the Golgi.  The cis 
face is the receiving side and is located near the RER.  The trans face of the 
GERL is the shipping side.  Overall, the GERL appears as a flattened stack of 
tubules with a slightly thicker membrane and a “fuzzy” substance (clathrin) 
coating the outside surface.  
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 Gonadotroph secretion.  Golgi apparati are especially extensive in cells 
specialized for secretion.  Once the secretory protein, in this case a hormonal 
substance (LH or FSH), is formed within the RER, the protein is enfolded in 
transport vesicles that bud like bubbles from a specialized region called 
transitional endoplasmic reticulum.  These specialized transport vesicles move 
the hormonal substance from the cisternae of the RER to the GERL.  These 
vesicles attach and fuse with the cisternae of the adjacent GERL and convey 
their substance into the site of the secretory granule formation.  
 After stimulation and formation of the secretory granules, a gonadotrope 
must release its secretory substance.  Mature secretory granules may leave the 
GERL on the trans face which gives rise to vesicles that are pinched off and 
move toward the cell surface to be discharged. Granules attach to the inside 
surface of the plasma membrane and fusion occurs at the contact point of the 
two membranes.  After fusion, the granule slips out via exocytosis (Caldani et 
al., 1993).  The hormone is released and travels to its target organ, the ovary. 
Interactions of the Hypothalamus and Adenohypophysis 
 Generating the LH surge.  The hypothalamus and adenohypophysis work 
together to produce the LH surge.  The hormonal cascade begins at the 
hypothalamus.  GnRH neurons are activated by a combination of internal and 
external stimuli as discussed previously.  GnRH is then released by the neurons 
into the vascular system via the hypothalamic-hypophyseal portal system, which 
shunts blood directly to the adenohypophysis.  GnRH binds to receptors on their 
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target cells the gonadotropes.  The GnRH receptor is a special transmembrane 
receptor.  When GnRH binds to the receptor, the end of the receptor protruding 
into the interior of the cell activates adenylate cyclase.  Adenylate cyclase then 
converts ATP into cyclic adenosine monophosphate (cAMP), a second 
messenger, in the cytoplasm of the cell.  The primary messenger is the hormone 
itself.  The cAMP system as the second messenger is an important step of the 
pathway because it is necessary before further downstream events can occur.  
Cyclic AMP plays an important role in the regulation of cellular function 
(Greenstein, 1994).  Activation of cAMP causes the activation of a family of 
control enzymes.  Protein kinase is activated by cAMP which in turn causes a 
conformational change in proteins by the addition of a phosphate group.   One of 
the functions of the second messenger system is the production and secretion of 
gonadotropin hormones.  After activation, the gonadotropes release the 
hormone (FSH or LH), whichever was specified by the frequency and amplitude 
of the GnRH pulses, by exocytosis.  The contents of the secretory vesicles are 
then released into the systemic bloodstream to seek their respective target 
tissues, the ovaries. 
 During diestrus, FSH release is due to the lower frequency release of 
GnRH.  As a follicle begins to mature and release estradiol-17β, GnRH 
frequency begins to increase.  This increase is due to the events discussed 
earlier which signal the GnRH neurons in the hypothalamus.  The increase in the 
frequency of GnRH release is the modified signal to gonadotropes that they neet 
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to produce and secrete more LH and less FSH.  In many species, ovulation 
occurs as a result of the increasing levels of LH (Shupnik, 1996). 
Ovary 
 Two-cell theory.  The “two-cell type, two gonadotropin theory” has been 
developed to explain follicular events of ovulation (Channing et al., 1978; and 
McNatty et al., 1980) (refer to figure 2).  A wave of FSH initiates follicular 
recruitment and initial growth as was previously discussed.  Around the end of 
diestrus, P levels decline which allows the intervals between GnRH pulses to 
increase.  An increase in pulse frequency of GnRH signals an increase in LH 
production and release from gonadotropes (Karsch, 1987).  The theca interna 
cells of the maturing follicle are directly affected by circulating LH.  Androgen 
production begins as LH attaches to the receptors on the surface of the theca 
cells.  The androgens then cross the basement membrane of the theca cells to 
reach the granulosa cells in the follicle.  The granulosa cells are the second cell 
in the “two-cell” theory.  The granulosa cell has receptors for FSH and LH, both 
gonadotropins affect androgen utilization by the cell.  In the granulosa cell, 
androgens are aromatized to estradiol-17β to aid in further estrus stimulation.  
Here the path becomes more complex as estradiol-17β has several functions at 
the follicular level.  One function is to act as a negative feedback control in the 
thecal cell, slowing down androgen production.  This control mechanism is 
achieved by decreasing the responsiveness of LH receptors on the thecal cell.  
Another function of estradiol-17β, in conjunction with FSH, is to increase 
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responsiveness of the granulosa cell receptors.  By increasing responsiveness 
of these receptors estradiol-17β can affect an increase in its own production to 
help prepare the follicle for ovulation.  The increasing estradiol-17β exerts a 
positive feedback control at the level of the hypothalamus and the gonadotropes 
by increasing GnRH release and responsiveness of the GnRH receptors.  
  
 
 
 
Figure 2.  Schematic representation of the hormonal pathway between the 
thecal and granulosa cells in the ovary.  Adapted from Greenstein (1996). 
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Altering Circulating Concentrations of LH   
Circulating LH concentrations, in the mare, can be altered as 
demonstrated by Garcia and Ginther (1978).  They demonstrated that estradiol-
17β and P regulated plasma LH in ovariectomized mares and that P lowered LH 
concentrations when administered alone.  When estradiol-17β was given alone, 
LH concentrations increased.  Furthermore, when P and estradiol-17β were 
administered together there was a greater retarding effect on circulating 
concentrations of LH than when P was given alone.  However, use of P and 
estradiol-17β showed no advantage for regulating LH in intact mares.  Garcia 
and Ginther (1978) showed that P has a suppressing effect and estradiol-17β 
has a positive effect on circulating concentrations of LH in ovariectomized 
mares.  This study demonstrated that P could be used to effectively decrease 
LH concentrations during estrus.  However, it was not shown that influencing LH 
affected estrus or follicular growth. 
The objective of this type of hormonal treatment is to delay not prevent 
ovulation.  Therefore, effects on level of LH suppression must be considered in 
selecting the hormonal treatment to be utilized.  Wiepz et al. (1988) compared 
altrenogest (2.2 mg/ml) and norgestomet (a progestin commonly used to 
synchronize estrus in cattle) and found similar concentrations of LH between the 
groups during the treatment period; however, concentrations of LH were 
consistently lower for the altrenogest group.  When the treatment was 
discontinued, LH concentrations for the altrenogest-treated mares demonstrated 
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a twenty times greater increase than did the norgestomet-treated group, and the 
LH rise began immediately following the withdrawal of treatment.  It is evident, 
therefore, that the effects of altrenogest can be fully reversed by discontinuing 
administration, thereby causing only a brief delay in LH secretion. 
Influence of Progestagens on the Estrous Cycle 
Naturally occurring and synthetic progestagens have proven effective for 
controlling estrus and ovulation in cycling females of other species (Loy and 
Swan, 1966).  Studies on the effect of exogenous progestagens on estrus and 
ovulation in cycling and non-cycling mares have been reported.  Loy and Swan 
(1966) found that estrus and ovulation could be suppressed in cycling mares by 
daily intramuscular injections of 100 to 400 mg of progesterone in oil.  
VanNiekerk et al. (1975) demonstrated that a normal, fertile estrus occurred 
within 3 to 4 days after cessation of daily injections of 100 to 125 mg of 
progesterone in oil in mares that were showing prolonged spring estrus.  
Injections were given for 7 to 9 days.  Webel and Squires (1975) reported that 
the synthetic progestagen, allyl trenbolone, effectively blocked estrus and 
ovulation in cycling mares when given as oral doses of 0.176 to 0.440 mg/kg of 
body weight.  Palmer (1979) was able to induce estrus and ovulation in 
anestrous pony mares in February and March.  Pony mares were fed 20 mg of 
allyl trenbolone daily for 10 d at the end of a two-month artificial photoperiod.  
Squires et al. (1979) reported that mares fed 0.44 mg allyl trenbolone/kg BW for 
12 d in March, commencing on the third day of physiological signs of estrus, 
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ovulated significantly ahead of control mares.  Allen et al. (1980) reported that 
10-15 d of Regumate® administered to anestrous mares resulted in behavioral 
estrus within eight days and ovulation within 18 d after treatment.  Turner et al. 
(1981) observed that altrenogest inhibited follicular growth.  After withdrawal, the 
inhibitory influence was released allowing increase in follicular size and ovulation 
of a smaller follicle than observed in control mares.  Evans et al. (1982) 
demonstrated that exogenous P administered daily inhibited the increase of LH 
during estrus, with subsequent ovulation failure of pre-ovulatory follicles in 
cycling mares.  Finally, Lofstedt and Patel (1989) showed that the ability of 
altrenogest to inhibit follicular growth was dependent on the stage of the estrous 
cycle when treatment began. 
There have been studies that provide speculation relative to the efficiency 
of altrenogest administration to control ovulation.  Lofstedt and Patel (1989) 
concluded that altrenogest was not effective for precise control of ovulation since 
3 of 4 mares treated on the first three days of estrus ovulated by approximately 
day 10 of a 15 day treatment and had follicular growth greater than or equal to 
35 mm.  Loy and Swan (1966) found that neither 50 nor 100 mg IM of P in oil per 
day stopped estrus or blocked ovulation when treatment started on day one of 
estrus.  Both of these studies utilized treatment regimens of 15 to 20 days of 
altrenogest administration and therefore do not provide information relating to 
short-term delay of ovulation.  
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Effect of Altrenogest on Pregnancy Rates 
In development of a protocol for altering the estrous cycle, it is imperative 
that the chemical agent used does not negatively affect fertility.  The use of 
altrenogest has shown no detrimental effects on conception rates when used in 
a protocol for estrus synchronization or for late transitional mares (Squires et al., 
1979, 1983).  Mares treated with oral allyl trenbolone (altrenogest) had 
pregnancy rates similar to untreated mares.  Additionally, Allen et al. (1980) 
treated 38 Thoroughbred mares with allyl trenbolone and reported that 55% 
conceived when bred during the estrus after treatment. 
Use of Progestins for Delaying Ovulation 
Three studies using short-term administration of altrenogest, in an 
attempt to delay ovulation, after selection of a dominant follicle in the mare are 
reported in the literature.   James et al. (1997) demonstrated that two days of 
altrenogest (0.044 mg/kg and 0.088 mg/kg body weight) administered at the 
beginning of standing estrus was successful for increasing the number of days 
to ovulation in mares with a 35+ mm follicle.  Bruemmer et al. (2000) 
demonstrated, in mares treated with 0.088mg/kg BW of altrenogest for two days, 
a delayed interval to ovulation when compared to controls.  However, in a 
second experiment that ran from June to August, there was no difference noted 
between altrenogest treated and control mares in days to ovulation.  Neither 
study reported negative effect on fertility whether altrenogest was administered 
at the recommended dose (0.044 m/kg BW) or double the recommended dose 
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(0.088 mg/kg BW).  James et al. (1997) reported period effects on days to 
ovulation during their study and therefore raised some questions on the 
effectiveness of Regumate to delay ovulation.  Furthermore, James et al. (1997) 
examined LH concentration in treated versus control mares but did not evaluate 
P or E concentrations between treated and control mares.  The current study 
was undertaken with those objectives in mind.  Bruemmer et al. (2000) 
evaluated days to ovulation, LH and P concentrations between treated and 
control mares, however; their study was conducted after the current study.  
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CHAPTER III 
EXPERIMENTAL PROCEDURES 
 
Animals 
Between February and July, twenty-six light body type mares ranging in 
from three to 23 years of age were used to study the efficacy of short-term 
altrenogest treatment for delaying ovulation with further evaluation of effects on 
fertility.   Six mares were owned by the Texas A&M University’s Department of 
Military Science, Parsons Mounted Cavalry (PMC).  Twenty mares were owned 
by the Department of Animal Science at Texas A&M University.  Four mares 
with foals, seven maiden mares and two open mares were maintained on native 
pastures at the TAMU Horse Center, College Station, TX.  The six PMC and 
seven Department of Animal Science mares used for riding instruction were 
housed at their respective teaching facilities until May.  At the end of the spring 
semester, these mares were moved to the TAMU Horse Center and remained 
on pasture for the duration of the project.  All mares were fed for maintenance or 
early lactation based on NRC requirements (NRC, 1989). 
Experimental design 
 Mares were assigned to one of four stallions, based on the need of the 
TAMU breeding program and then randomly assigned to either a treatment 
(0.044 mg/kg altrenogest) or a control (Neobee M5 oil, carrier oil for Regumate®) 
group (see Table 1).  The progestin (altrenogest) administered was Regumate® 
 23
(chemical name: 17α-Allyl-17β-hydroxyestra-4,9,11-trien-3-one, Hoechst 
Roussel, Frankfurt, Germany).  The manufacturer’s recommended dose of 
Regumate® is 1 ml/110 lbs of body weight (0.044 mg/kg) because each ml of 
Regumate® contains 2.2 mg of altrenogest (0.22% or 2.2 mg/ml) in an oil 
solution (Neobee M5 oil).  It was determined by James et al. (1997) and 
Bruemmer et al. (2000) that the recommended dose of Regumate® provided the 
most reliable results. 
 
Table 1.  Experimental design and assignment of mares to stallion and 
treatment. 
 
 
  DundeeColonel     SkipAStake Starman EyesLegacy   
 
Control NuEnt (3)            MO (3) FL (3)  Starlet (3) 
  NuRey (4)            Skippy (6) Mercury (4)  
  CB (5)             Dixie (18) Diane (11) 
  Merrily (5)    Polly (23) 
  Mandy (11) 
Treated NBM (3)  Maria (3) TF (3)  PC (4) 
  NNN (4)  MM (6) Lady (5) 
  Snip (5)  Babe (20) CC (11) 
  Binky (14)    Sparticus (18) 
  Ashley (13)   
 
 
 
 
Mares were teased daily by a stallion confined to a teasing cage located 
in the center of a paddock in which the mares were placed.  Follicular activity 
was monitored by palpation and real time ultrasonography (Sonovet 600®, 
Universal Medical Systems, Inc., Bedford Hills, NY).  Mares in both groups 
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received their first oral dose once a 35mm (an industry standard) or greater 
follicle was detected via ultrasound.  Mares in the treatment group received 
altrenogest orally for two days and were artificially inseminated every other day, 
starting on the first day of treatment, until ovulation.  Mares in the control group 
received Neobee M5 oil orally for two days and were artificially inseminated 
every other day starting on the first day of administration of carrier oil until 
ovulation.  Detection of pregnancy was determined by ultrasound on day 12 
post-ovulation and embryonic growth was assessed on day 14 and day 16.  
Prostaglandin (10 mg Lutalyse®, Upjohn, Kalamazoo, MI) was administered on 
day 16 to mares which were not part of the TAMU Department of Animal 
Science broodmare band.  The injection of prostaglandin terminated 
pregnancies on the six PMC and seven Department of Animal Science mares 
and allowed them to return to their previous uses in riding instruction. 
Semen Collection, Evaluation and Processing 
 All four stallions were known to be fertile based on past breeding 
histories.  Semen was collected and processed in the same manner for each 
stallion and each insemination dose.  During the collection, the ejaculate was 
filtered in line to remove the gel fraction.  A small amount of the ejaculate was 
used to assess spermatozoal motility and concentration.  Spermatozoal motility, 
a visual estimation of the percentage of spermatozoa that are progressively 
moving forward, was determined using a light microscope at 400 X 
magnification.  Spermatozoal motility (%) was assessed by the same individual 
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throughout the study to minimize variation of this parameter.  Concentration was 
determined using a Densimeter® (Model 534A, Animal Reproductive Systems, 
Chino, CA).  Each insemination dose contained a minimum of 500 million motile 
sperm cells extended at a 1:1 ratio with E-Z Mixin®-“OF” or E-Z Mixin®-“CST” 
(Animal Reproduction Systems, Chino, CA) semen extender. 
Sample Collection 
 Baseline blood samples were collected daily for each mare one estrous 
cycle prior to the treatment estrous cycle via jugular venipuncture.   One blood 
sample per day is all that is necessary since the accumulative signal, not the 
pulses, are the focus of the project.  During the time of administration of 
altrenogest or carrier oil and until three days post-ovulation, blood samples were 
collected twice a day (at 12 h intervals).  In the mare, the LH peak is one to two 
days after ovulation so the last blood collection day was on the third day post-
ovulation.  Blood was collected into 10 ml sodium heparin vacutainers and 
cooled to 4 to 6°C.  All vacutainers were centrifuged at 2500 x g for 15 min.  The 
plasma was removed and aliquoted equally into three 2 ml microcentrifuge 
tubes, taken to the laboratory, frozen and stored at -20°C for later analysis.  
Plasma samples were analyzed for LH, progesterone and estradiol using 
radioimmunoassay (RIA) techniques. 
Hormone Analyses 
 Plasma hormone concentrations were determined from daily baseline 
samples collected during the pre-treatment period.  Beginning with the first day 
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of treatment through day three post-ovulation, analysis was conducted from 
samples collected every 12 h (twice daily) that were pooled into one composite 
sample for each day.  All samples were assayed in duplicate.  Plasma LH 
concentrations were also determined from the 12 h samples for comparison to 
the composite sample. 
Plasma LH concentrations were determined using the Roser LH RIA 
protocol (Matteri et al., 1987) that had been previously validated (Lang et al., 
1995) with several modifications.  The first antibody (518B7, mouse anti-equine, 
Dr. J.F. Roser, UC Davis, CA) was diluted 1:30,000 in PBS-EDTA-normal 
mouse serum instead of RIA buffer.  The second antibody (goat anti-mouse, 
Antibodies Inc., Davis, CA) was diluted 1:40 in PBS-EDTA instead of 
Polyethylene glycol (PEG).  Standards (AFP5130A, eLH, Dr. A.F Parlow, 
Torrence, CA) and I125-LH were diluted with PBS-Gelatin instead of RIA buffer.  
The use of Chloramine T for iodination in place of iodogen was another 
modification of the Roser protocol.   
A 10 DG column (Bio-Rad, Hercules, CA) was conditioned with PBS and 
PBS-Gelatin.  Approximately 7 µg of equine luteinizing hormone antigen (Dr. 
A.F. Parlow, Harvor-UCLA Medical Center, Torrance, CA, AFP-240580R6) was 
added to a reaction vial, followed by 1.0 mCi NaI125, (NEN Life Sciences, 
#NEZ033A) and 10 µl Chloramine T at a dilution of 0.5 mg/ml.  The reaction vial 
was mixed on ice for 15 sec and then transferred onto the conditioned column.  
The column was eluted with 10 ml of PBS-Gelatin and one ml fractions were 
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collected into labeled glass tubes.  The fraction with the highest protein peak 
was further diluted to 15,000 cpm/100 µl.  This stock I125-LH was stored at 4°C 
for later use.   
 On the first day of the assay, 100 µl PBS-Gelatin, 100 µl standard or 
unknown sample, 200 µl first antibody and 100 µl of I125-LH were added into the 
respective glass tubes and incubated at room temperature for 24 h.  The 
following day, 200 µl of second antibody and 1 ml of cold 5% PEG were added 
to each tube.  Tubes were centrifuged, decanted and counted for one minute.  
Sensitivity of the assay was 0.03 ng/ml.  For 12 assays, the intra- and inter-
assay coefficient of variation was 2.8% and 12.57%, respectively. 
 Plasma progesterone concentrations were determined using a single 
antibody RIA kit (Coat–a-Count®, DPC, Los Angeles, CA).  Sensitivity of the 
assay was 0.02 ng/ml.  For four assays, the intra- and inter-assay coefficient of 
variation was 6.12% and 4.11%, respectively. 
 Plasma estradiol concentrations were determined using a double 
antibody RIA kit (Double Antibody, DPC, Los Angeles, CA).  Sensitivity of the 
assay was 0.46 pg/ml.  For four assays, the intra- and inter-assay coefficient of 
variation was 5.97% and 8.7%, respectively. 
Statistical Analysis 
 Data were subjected to analysis of variance using procedures appropriate 
for a randomized complete block (2 X 4) design using the general linear model 
(GLM) procedure of SAS (SAS Inst. Inc., Cary, NC).  The main effects of mare, 
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treatment, days to ovulation as well as their interactions were analyzed.  Mean 
follicle size at ovulation was evaluated using the student’s t-test.  Pregnancy 
rates were examined using Chi-Square procedures to determine reproductive 
efficiency (Hoshmand, 1988). 
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CHAPTER IV 
RESULTS 
 
Days to Ovulation 
 Number of days to ovulation for individual mares is shown in Table 2.  
Number of days to ovulation for treated and control groups is shown in Table 3.  
Similar to the findings of James et al. (1997) and Bruemmer et al. (2000), there 
was a difference (p<.05) between the treated and control groups in days to 
ovulation.  Mean days to ovulation from day one of treatment for treated and 
control mares were 6.10 ± 3.41 d and 3.23 ± 2.0 d, respectively. To further 
examine the effect on days to ovulation, each group was divided into 3 periods, 
mares that ovulated in 1 to 3 d, 4 to 6 d and 7 to 14 d.  Analysis of the 3 periods 
using an unpaired t test yielded a significant difference between groups (p<.05) 
(Table 4).  Nine of the 13 control mares had ovulated within three days of 
starting treatment.  Only two of the 13 treated mares had ovulated by day three.  
During the four to six days following treatment, three of the remaining four 
control mares and seven of the remaining eleven treated mares had ovulated.  
Finally, in the last period, days seven to 14 after starting treatment, the last 
control mare ovulated on day 8 and the remaining four treated mares ovulated.  
The number of mares that ovulated by d 2 and by d 6 during the treatment and 
control periods is shown in Table 5.   
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Table 2.  Number of days to ovulation for individual mares treated with 
altrenogest vs controls. 
 
 
             Control                Treated   
Mare Day Mare Day 
 
Nu Ent 2 NBM 5.5 
Nu Rey 3 NNN 12 
CB 8 Snip 4 
Merrily 3 Binky 5 
Mandy 3.5 Ashley 6 
MO 1 Maria 7 
Skippy .5 MM 4.5 
Dixie 2 Babe 3 
FL 2.5 TF 14 
Mercury 3 Lady 7.5 
Diane 5 CC 4 
Polly 3 Sparticus 4 
Starlet 5.5 
 
PC 2.5 
 
 
 
  
 
 
 
Table 3.  Effect of altrenogest administration on days to ovulation for mares 
treated with altrenogest vs controls. 
 
      n   Days to Ovulation 
 
Control    13        3.23 ± 2.00a 
Treated    13        6.10 ± 3.41b 
Values are LSMeans ± SE 
a,b Columns lacking a common superscript differ (p<.05) 
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Table 4.  Number of days to ovulation for mares treated with altrenogest vs 
controls separated into periods. 
 
   Day 0-3  Day 4-6  Day 7-14 
 
Control  9a        3a                   1a   
Treated  2b        7b         4b   
 
a,b Columns lacking a common superscript differ (p<.05) 
 
 
 
 
Table 5.  Number of mares that ovulated by day 2 and day 6 after treatment with 
altrenogest vs controls. 
 
       Number of mares that ovulated 
 
Group   n    Day 2  Day 6 
Control  13        1      12 
Treated  13        0        9 
 
 
 
 
During the early part of this study, three maiden mares experienced a 
longer interval to ovulation, most likely the result of the spring transition.   
Furthermore, in each group (treated and control) there was one mare that 
developed a large follicle, underwent follicle regression and then switched to a 
secondary follicle on the other ovary which resulted in a prolonged interval to 
ovulation.  Finally, one control mare ovulated a 35 mm follicle on the evening of 
the first day of treatment, thereby having an extremely short interval to ovulation. 
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Follicular Activity 
 
 Maximum follicular diameter for individual treated and control mares are 
shown in Table 6.  Mean follicular diameters (mm) for treated and control groups 
were 43.62 ± 5.11 and 43.08 ± 6.75, respectively (Table 7).  There was no 
difference (p>.05) between groups in mean follicular diameters at ovulation.  
This corroborates the findings of James et al. (1997).  
 
 
Table 6.  Follicular diameter (mm) for individual mares treated with altrenogest 
vs controls. 
 
Control   Treated   
 
Nu Ent 45 NBM 42 
Nu Rey 45 NNN 50 
CB 52 Snip 47 
Merrily 48 Binky 50 
Mandy 45 Ashley 46 
MO 37 Maria 43 
Skippy 35 MM 48 
Dixie 41 Babe 48 
FL 41 TF 45 
Mercury 47 Lady 52 
Diane 57 CC 46 
Polly 40 Sparticus 38 
Starlet 49 PC 40 
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Table 7.  Effect of altrenogest administration on follicular diameter at ovulation 
for treated vs controls. 
 
Group    n   Follicular Diameter at Ovulation 
 
Control   13    44.77 ± 1.44 
Treated   13    45.77 ± 1.44 
 
Values in column are LSMeans ± SE 
 
 
Luteinizing Hormone 
 Luteinizing hormone concentrations were measured from daily pre-
treatment plasma samples.  From the beginning of treatment to three days post-
ovulation, both 12 h samples and the pooled, composite samples were 
analyzed.  Due to the variation of the interval between treatment and the number 
of days to ovulation, there were different numbers of samples for individual 
mares.  Utilizing an unpaired t test, no significant difference was found between 
the mean of the 12 h samples and the pooled samples; therefore, the focus will 
be on the pooled samples.  Mean composite peak LH concentration (ng/ml) for 
treated versus controls was 6.85 ± 0.54 and 10.10 ± 0.54, respectively.  There 
was no effect of treatment on LH concentration for treated versus control mares.  
Figure 3 shows LH concentration of treated mares versus controls with day 0 as 
the day of ovulation.  Although altrenogest did not significantly affect LH, the LH 
peak for treated mares was diminished as compared to the control group (Figure 
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3).  This is similar to what James et al. (1997) reported.  Bruemmer et al. (2000) 
also examined LH in one of their two studies.  They reported a difference for 
treated mares in the amplitude of their LH peak versus controls.   
Figure 4, shows the composite LH concentrations, with day 0 as the first 
day of treatment.  The altrenogest treated mares do exhibit lower LH 
concentrations than the control mares on the two days of treatment, but then 
demonstrated increased LH within 24 hours after the second day of treatment.  
James et al. (1997) and Bruemmer et al. (2000) examined LH concentration 
around ovulation and not around the treatment period.  
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Figure 3.  Composite LH concentration with day 0 as ovulation for mares treated 
with altrenogest vs controls. 
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Figure 4.  Composite LH concentration with d 0 as the first day of treatment for 
mares treated with altrenogest vs controls.   
 
 
 
Progesterone 
 There was no effect of altrenogest treatment on progesterone 
concentrations for treated versus control mares (P=0.56).  This is similar to the 
results of Bruemmer et al. (2000).  Figure 5 illustrates the progesterone 
concentrations of altrenogest treated mares versus controls with day 0 as the 
day of ovulation.  Progesterone levels during estrus, for both treated and control 
groups, are low (<1 ng/mL) two days prior to ovulation and begin to increase 
rapidly the two days following ovulation.   
 Figure 6 shows P concentrations of altrenogest treated mares versus 
controls with day 0 as the first day of treatment.  Altrenogest treated mares 
exhibit a decline in P after the first day of treatment and levels do not start to 
increase until two days after the second day of treatment.   
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The progesterone levels are indicative of the native progestins released 
from the corpus luteum.  The administration of Regumate® does not cross react 
with the RIA and therefore does not add to the values obtained by the assay. 
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Figure 5. Progesterone concentration with day 0 as ovulation for mares treated 
with altrenogest vs controls.  
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Figure 6.  Progesterone concentration with day 0 as the first day of treatment for 
mares treated with altrenogest vs controls. 
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Estradiol 
 There was no effect of altrenogest treatment on estradiol concentrations 
for treated versus control mares (P=.67).  Allen (1995) reported estradiol levels 
in barren and maiden mares to range from 5-20 pg/mL and in lactating mares to 
range from 150-200 pg/mL.  The current study had four lactating mares, two 
control mares (300-600 pg/mL) and two treated mares (300-1400 pg/mL) with 
extremely high estradiol concentrations compared to the other mares.   
Figure 7 shows estradiol concentrations with day 0 as the day of 
ovulation.  Figure 8 shows estradiol concentration with day 0 as the day of 
ovulation for altrenogest treated mares versus control minus the four mares 
whose estradiol concentrations were outside the normally expected parameters.  
Both graphs illustrate the altrenogest treated and control mares have peak 
estradiol levels two days prior to ovulation which is characteristic of the 
preovulatory peak of estradiol.  Estradiol levels then decline and remain low 
through ovulation and the end of the collection period.   Figure 8 is more 
characteristic of the hormonal profile of E during this time of the estrous cycle.   
Figure 8 further shows that the treatment regimen did not affect the E curve. 
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Figure 7.  Estradiol concentration with day 0 as ovulation for mares treated with 
altrenogest vs controls. 
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Figure 8.  Estradiol concentration with day 0 as ovulation for mares treated with 
altrenogest vs controls (minus four mares whose E concentrations were outside 
normally expected parameters). 
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Figure 9 shows estradiol concentrations with day 0 as the first day of 
treatment.  The altrenogest treated mares had overall higher concentrations of 
estradiol throughout the collection period and that can be noted in this figure.  
Figure 10 shows estradiol concentration with day 0 as the day of ovulation with 
the outlier mares removed from the mean.  The figure includes the days with the 
most available data.  Both the altrenogest treated and control mares 
demonstrate increasing estradiol concentration approaching the first day of 
treatment and continuing five days post treatment.  Most of the control mares 
have ovulated by three days post treatment therefore the graph does not extend 
beyond this time frame.    
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Figure 9.  Estradiol concentration with day 0 as the first day of treatment for 
mares treated with altrenogest vs controls. 
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Figure 10.  Estradiol concentration with day 0 as the first day of treatment for 
altrenogest treated mares vs controls (minus four mares whose E concentrations 
were outside normally expected parameters). 
 
 
 
Pregnancy Rates 
There was no effect of altrenogest treatment on pregnancy rates.  This is 
in agreement with of James et al. (1997) and Bruemmer et al. (2000).  
Pregnancy rates were examined to determine the effect of altrenogest treatment, 
during estrus on the reproductive efficiency of the mares.  The number of treated 
mares pregnant 12 days after ovulation was 11 out of 13, whereas the number 
of control mares that were pregnant 12 days after ovulation was 10 out of 13 
(Table 9).   Chi-square (0.23) was less than the critical value (3.84) concluding 
that the pregnancy rates were the same for altrenogest treated and control 
mares. 
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Table 8.  Pregnancy rates for individual mares treated with altrenogest vs 
controls. 
 
Control   Treated   
 
Nu Ent P NBM P 
Nu Rey P NNN P 
CB P Snip P 
Merrily P Binky NP 
Mandy P Ashley P 
MO NP Maria P 
Skippy P MM P 
Dixie NP Babe NP 
FL P TF P 
Mercury P Lady P 
Diane P CC P 
Polly NP Sparticus P 
Starlet P PC P 
 
 
 
 
 
 
Table 9.  Pregnancy rates for mares treated with altrenogest versus controls. 
 
     Number of            Pregnancy 
     Mares Pregnant     Rate (%) 
 
Group   n      
Control  13   10           77 
Treated  13   11           85 
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Embryonic development was also evaluated by ultrasonography on d14 
and d16 for treated and control mares.  Utilizing an unpaired t test on the data 
available there was no difference (P=.34, .90 and .69) in size of the embryonic 
vesicle on d12, d14 and d16, respectively, for altrenogest treated versus control 
mares (Table 10).  
 
Table 10.  Size of Embryonic Vesicle on d12, d14 and d16 after ovulation for 
mares treated with altrenogest versus controls. 
 
Group    n  d 12     d 14          d 16   
 
Control 10      10.67 ± 3.01      15.00 ± 3.16  25.16 ± 2.40 
Treated   9             9.28 ± 2.05             15.33 ± 4.80  25.80 ± 2.77 
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CHAPTER V 
GENERAL DISCUSSION 
 
Days to Ovulation 
 Number of days to ovulation did show significant differences between the 
altrenogest treated mares and the control mares.  Analysis of both groups that 
were divided into three periods also demonstrated a significant difference in 
days to ovulation between treated and control mares.  Although the data are 
significant, there were two treated mares that ovulated by the third day after 
treatment and one control mare that ovulated after six days.  Therefore, even 
though the treated mares had a significantly longer days to ovulation, the 
treatment still demonstrated some variability.   
Palmer (1978) reported that the length of the follicular phase is dependent 
on the degree of follicular development based on circulating estrogen levels at 
the time of luteolysis.  At the time of luteolysis, the length of the follicular phase 
and estrogen levels were negatively correlated.  However, just prior to ovulation 
the length of the follicular phase and estrogen levels were positively correlated.  
Furthermore, Douglas and Ginther (1976) demonstrated that a single injection of 
prostaglandin significantly shortened the interovulatory interval.  In the current 
study prostaglandin was administered to regress the corpus luteum after the 
baseline estrous cycle ovulation.  Therefore, high estradiol levels at the time of 
either induced or natural luteolysis may have resulted in a decrease in the 
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number of days to ovulation for some mares in either the treated or control 
group. 
Sirois et al. (1989) reported that the diameter of the preovulatory follicle at 
the time of progesterone decline was negatively correlated with the length of the 
follicular phase.   Insufficient follicular data prevented analysis of this relationship 
for the current study.  However, it could be a factor for either an increase or a 
decrease in the number of days to ovulation. 
Follicular Activity 
There was no difference between the altrenogest treated and control 
mares in size of follicle at ovulation.  One factor that could have been avoided is 
when each mare was started on the project.  The data would have been more 
representative if all of the mares had had a regular estrous cycle before the 
onset of the project.   This study utilized mares in all phases of the breeding 
season; there were some maiden mares, spring transitional mares and mares 
going through foal heat.  In order to get a better understanding of how 
altrenogest administration during estrus affects a mature follicle, larger numbers 
of mares from each parity group mentioned should be evaluated.     
Bruemmer et al. (2000) reported that altrenogest treated mares had a 
greater incidence of follicular regression than did control mares.  Those findings 
agree with Evans et al. (1982) which showed exogenous progesterone not only 
decreased LH concentrations but also resulted in failure of preovulatory follicles 
to ovulate.  James et al. (1997) did not report on follicular regression.  Every 
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mare in the current study had a cycle that resulted in an ovulation.  However, 
there was one altrenogest treated and one control mare that did experience 
follicular regression in which they switched from a dominant follicle on one ovary 
to a dominant follicle on the other ovary.  Both mares started with a large follicle 
on both ovaries.  Examination of when the LH peak occurred corroborates that 
those mares did indeed switch dominant follicles and did not ovulate the first 
follicle.  Another determination of ovulation in those mares was examination of 
progesterone levels.  To differentiate ovulation and follicular regression plasma 
progesterone will increase and remain above 5ng/mL if an ovulation has 
occurred.  Neither mare in question had an increase of progesterone during 
follicular regression. Results of the current study indicate that altrenogest 
treatment does not alter the final size a follicle will reach prior to ovulation.  
Instead it will only slow the growth necessary to reach the predetermined 
ovulatory size.    
Luteinizing Hormone 
 Luteinizing hormone concentrations were analyzed beginning five days 
prior to treatment in order to obtain baseline values and continuing until three 
days post-ovulation.  Similar to the results of James et al. (1997), there was not 
a significant difference in LH concentrations but a trend did exist such that the 
control mares demonstrated higher LH concentration during the test period 
compared to the altrenogest treated group.  As demonstrated by Figure 4, the 
LH curve for the control mares resembles a normal LH profile whereas the curve 
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for the altrenogest treated mares was broader and the altrenogest treated mares 
demonstrated diminished amplitude in their LH peak.  This supports the 
hypothesis that altrenogest administration during the follicular phase might alter 
the preovulatory surge of LH.  Squires et al. (1983) and Lofstedt and Patel 
(1989) reported that LH is only slightly suppressed by altrenogest.  Bruemmer et 
al. (2000) demonstrated a difference between treated and control groups in the 
amplitude of the LH peak.    Their study administered twice the recommended 
dose of Regumate® and that may account for the significant difference.  Wiepz 
et al. (1988) demonstrated that altrenogest can suppress or lower LH 
concentration.  Figure 3 shows the effect of altrenogest on LH levels.  Although 
not significant, there is a decrease in LH seen during the two days of altrenogest 
administration for the treated mares.  
Progesterone 
 Progesterone concentrations were analyzed daily beginning five days 
prior to treatment for baseline values, and continuing until three days post-
ovulation in an attempt to note differences in subsequent luteal function.  There 
were no differences in P concentrations between altrenogest and control mares.  
This agrees with Bruemmer et al. (2000) in which no difference was observed in 
progesterone concentrations even when doubling the recommended dose of 
altrenogest.  There was a decline in P for the altrenogest treated mares on the 
second day of treatment and on the subsequent day.  This decline corresponds 
with the high concentration of estradiol exhibited in two of the treated mares.  
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When P concentration is low (as they are at this point of the estrous cycle) 
estradiol concentration is high and predominates.   
Estradiol 
 Estradiol concentrations were also analyzed daily beginning five days 
prior to treatment for baseline values, and continuing until three days post-
ovulation to evaluate the inhibitory effect of an exogenous progestin on follicular 
steroid secretions.  Estradiol secretion is at its highest in the absence of 
progesterone (concentrations <1ng/mL).  Estradiol concentrations increase 
progressively six to eight days before ovulation (at the beginning of the follicular 
phase or estrus).  Follicular estradiol-17β and estrone sulfate peak one to two 
days prior to ovulation.  It is the surge of estrogens that initiates LH release.  At 
ovulation estradiol concentrations have been decreasing and will reach baseline 
diestrus levels near the end of estrus (within two days post-ovulation).  Both 
groups in this study follow this pattern of secretion.  Both groups seem to have a 
peak one to two days prior to ovulation.  Also, both groups demonstrated a 
decline in estradiol beginning one day after ovulation which coincides with the 
rise in progesterone.  Therefore, there appears to be no inhibitory effect of an 
exogenous progestin on estradiol secretion.  
Pregnancy Rates 
 Pregnancy rates were analyzed to determine whether treatment with 
altrenogest to delay the time of ovulation would be detrimental to viability of the 
oocyte.  Pregnancy rates for altrenogest treated and control mares were 85% 
 48
and 77% respectively.  There was no significant difference in pregnancy rates 
between the two groups.  This supports previous reports by James et al. (1997) 
and Bruemmer et al. (2000) that fertility was not affected by short-term 
altrenogest administration during the follicular phase. 
 Ultrasonographic examination was conducted on d 14 and d 16 post-
ovulation to determine whether altrenogest administration had any detrimental 
effects on early embryonic development.  The average size of the embryonic 
vesicle calculated with the available data for d 14 and d 16 in altrenogest treated 
versus control mares were 15.33 ± 4.80, 25.8 ± 2.77 and 15.00 ± 3.16, 25.17 ± 
2.40, respectively.  Short-term administration of altrenogest appears to have no 
detrimental effects on pregnancy rates or on early embryonic development.        
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CHAPTER VI 
CONCLUSIONS 
 
 The efficacy of short term altrenogest administration in delaying ovulation 
was evaluated using twenty-six mares of light body type that ranged from three 
to 23 years of age.  The hypothesis tested was that mares treated with 
altrenogest for two days would exhibit a delay in ovulation versus control mares.  
Mares were allocated to one of four stallions and then randomly assigned to 
either a treatment or control group.   Treated mares received two consecutive 
oral doses of Regumate® once a 35 mm or greater follicle had developed.  
Control mares received two oral doses of Neobee M-5 oil.  Blood samples were 
drawn daily beginning with the estrous cycle preceding the treated cycle.  During 
the treated cycle, blood was collected daily with the following exception; blood 
was collected twice a day starting on the first day of altrenogest or oil 
administration and continuing until three days post-ovulation.  In addition to 
analyzing days to ovulation, hormone concentrations (LH, progesterone and 
estradiol) and pregnancy rates were evaluated.  
 Days to ovulation for mares treated with altrenogest versus mares in the 
control group was longer (P<0.05).  Mean days to ovulation for altrenogest 
treated mares was 6.10 ± 3.41.  Mean days to ovulation for the control mares 
was 3.23 ± 2.00. 
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 Luteinizing hormone, progesterone and estradiol concentrations were not 
statistically different between altrenogest treated and control mares (P=0.27, 
P=0.56, P=0.67).  Therefore, hormone concentrations were not significantly 
affected by treatment.  However, there was a trend for those mares treated with 
altrenogest to have an overall lower LH concentration and a diminished peak as 
compared to control mares.  The expected result of altrenogest treated mares 
exhibiting a delay in their LH peak versus controls was not seen.  
Evaluation of pregnancy rates is important to provide credibility before 
this treatment regimen is accepted for use by equine breeding facilities.  
Pregnancy rates were not different (P>0.05) between altrenogest treated (85%) 
and control groups (77%).  Therefore, reproductive efficiency was not affected 
by treatment.  Further, embryonic development was not detrimentally affected by 
treatment. 
 An important aspect of breeding management involves the determination 
of when ovulation will occur.  This determination is necessary for artificially 
inseminating as close to the time of ovulation as possible while minimizing the 
number of inseminations per cycle.  Although this study did provide evidence to 
conclude that short-term altrenogest administration does delay ovulation of a 
mature follicle, the treatment regimen requires further study.   A field study 
utilizing larger numbers of mares in a variety of commercial breeding facilities 
would provide further credibility for a treatment regimen using Regumate® during 
estrus to delay ovulation.       
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APPENDIX 
 
RAW DATA FOR DAYS UNTIL OVULATION, LH, PROGESTERONE, 
ESTRADIOL CONCENTRATION 
 
mare tx/age d of ov d of tx LH P E PG 
Ashley tx/13 -11 -5 0 9.2 3 P 
Ashley barren -10 -4 0 9.5 3  
Ashley  -9 -3 0 11.6 4  
Ashley  -8 -2 0 10 6  
Ashley  -7 -1 0 8.3 6  
Ashley  -6 0 0 7.6 8  
Ashley  -5 1 0 5.5 12  
Ashley  -4 2 0 0.8 16  
Ashley  -3 3 0 0.4 23  
Ashley  -2 4 0.7 0.1 28  
Ashley  -1 5 2.5 0.05 39  
Ashley  0 6 3.5 0.05 31  
Ashley  1 7 4.4 0.5 30  
Ashley  2 8 5.0 1.9 33  
Ashley  3 9 1.7 4.4 26  
Babe tx/20 -8 -5 3.5 0.9 27 NP 
Babe barren -7 -4 3.4 0.4 17  
Babe  -6 -3 2.6 0.2 23  
Babe  -5 -2 2.9 0.07 20  
Babe  -4 -1 4.3 0.09 24  
Babe  -3 0 4.9 0.1 31  
Babe  -2 1 4.2 0.08 31  
Babe  -1 2 5.7 0.07 32  
Babe  0 3 5.9 0.2 25  
Babe  1 4 7.5 1.0 25  
Babe  2 5 5.4 2.7 32  
Babe  3 6 2.9 4.8 29  
Binky tx/14 -12 -7 6.3 1.5 9 NP 
Binky barren -11 -6 5.6 0.5 11  
Binky  -10 -5 5.7 1.2 6  
Binky  -9 -4 5.9 0.2 12  
Binky  -8 -3 6.2 0.1 17  
Binky  -7 -2 . 0.1 17  
Binky  -6 -1 4.9 0.1 23  
Binky  -5 0 5.5 0.1 34  
Binky  -4 1 6.2 0.1 37  
Binky  -3 2 7.6 0.1 37  
Binky  -2 3 6.8 0.2 45  
Binky  -1 4 7.5 1.5 40  
Binky  0 5 5.0 3.6 35  
Binky  1 6 4.7 9.0 33  
Binky  2 7 3.6 13 31  
CC tx/11 -7 -3 0 12.1 23  
CC  -6 -2 1.4 1.2 13  
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RAW DATA FOR DAYS UNTIL OVULATION, LH, PROGESTERONE, 
ESTRADIOL CONCENTRATION (CON’T) 
 
mare tx/age d of ov d of tx LH P E PG 
CC  -5 -1 1.8 0.3 17  
CC  -4 0 2.8 0.1 29  
CC  -3 1 3.0 0.08 30  
CC  -2 2 3.5 0 32  
CC  -1 3 5.7 0.04 34  
CC  0 4 8.0 0.1 32  
CC  1 5 8.5 1.1 27  
CC  2 6 7.1 2.5 26  
CC  3 7 5.9 4.8 26  
CC  4 8 3.3 6.6 21  
CandyBar c/5 -13 -5 0 0.04 7 PG 
CandyBar  -12 -4 0.6 0.06 7  
CandyBar  -11 -3 0.2 0.02 5  
CandyBar  -10 -2 1.6 0.08 5  
CandyBar  -9 -1 1.1 0 6  
CandyBar  -8 0 0.9 0.03 7  
CandyBar  -7 1 2.0 0.06 7  
CandyBar  -6 2 2.1 0.09 10  
CandyBar  -5 3 2.6 0.04 9  
CandyBar  -4 4 3.4 0.1 13  
CandyBar  -3 5 4.6 0.09 20  
CandyBar  -2 6 6.5 0.08 21  
CandyBar  -1 7 8.7 0.07 15  
CandyBar  0 8 8.9 0.6 18  
CandyBar  1 9 7.5 3.0 14  
CandyBar  2 10 5.2 5.5 11  
CandyBar  3 11 3.5 8.8 12  
CandyBar  4 12 2.0 9.7 9  
Diane c/11 -10 -5 0.6 12.7 9 PG 
Diane  -9 -4 0.9 11.9 13  
Diane  -8 -3 1.6 1.7 8  
Diane  -7 -2 2.6 0.7 8  
Diane  -6 -1 . 0.3 8  
Diane  -5 0 3.5 0.2 11  
Diane  -4 1 3.8 1.7 10  
Diane  -3 2 4.1 0.06 16  
Diane  -2 3 5.2 0.05 21  
Diane  -1 4 6.4 0.08 19  
Diane  0 5 8.1 0.2 24  
Diane  1 6 9.5 1.2 17  
Diane  2 7 8.4 4.2 17  
Diane  3 8 7.4 11.2 16  
Dixie c/18 -7 -5 6.8 0 0  
Dixie  -6 -4 6.9 0 0 NP 
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RAW DATA FOR DAYS UNTIL OVULATION, LH, PROGESTERONE, 
ESTRADIOL CONCENTRATION (CON’T) 
 
mare tx/age d of ov d of tx LH P E PG 
Dixie  -5 -3 6.6 0 1  
Dixie  -4 -2 8.6 0 2  
Dixie  -3 -1 7.4 0 3  
Dixie  -2 0 8.2 0 4  
Dixie  -1 1 9.0 0 4  
Dixie  0 2 9.0 0.1 3  
Dixie  1 3 13.3 1.2 1  
Dixie  2 4 9.5 3.1 2  
Dixie  3 5 9.3 4.3 1  
Dixie  4 6 6.9 7.9 3  
FoxyLady c/3 -2 0 1.5 0.04 4  
FoxyLady  -1 1 2.9 0.03 9  
FoxyLady  0 2 5.0 0.02 12  
FoxyLady  1 3 6.1 0.5 7  
FoxyLady  2 4 5.8 2.4 5  
FoxyLady  3 5 3.8 4.9 4  
FoxyLady  4 6 2.6 7.2 2  
FoxyLady  5 7 2.8 9.6 1  
Lady tx/5 -10 -3 3.6 1.7 7  
Lady  -9 -2 3.5 0.6 11  
Lady  -8 -1 3.7 0.3 12  
Lady  -7 0 3.8 0.1 9  
Lady  -6 1 4.0 0.1 13  
Lady  -5 2 5.3 0.1 4  
Lady  -4 3 4.5 0.09 13  
Lady  -3 4 4.6 0.04 14  
Lady  -2 5 4.3 0.03 13  
Lady  -1 6 6.5 0.02 20  
Lady  0 7 10.1 0.03 18  
Lady  1 8 11.2 0.4 18  
Lady  2 9 11.3 2.4 15  
Lady  3 10 7.7 4.9 13  
Lady  4 11 6.3 7.9 14  
MM tx/6 -9 -5 2.6 20.4 33 PG 
MM  -8 -4 3.0 1.4 31  
MM  -7 -3 3.8 0.7 27  
MM  -6 -2 3.8 0.3 28  
MM  -5 -1 4.6 0.2 34  
MM  -4 0 5.5 0.1 29  
MM  -3 1 4.8 0.2 41  
MM  -2 2 7.3 0.1 45  
MM  -1 3 8.9 0.1 35  
MM  0 4 12.2 0.1 41  
MM  1 5 13.1 1.0 34  
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RAW DATA FOR DAYS UNTIL OVULATION, LH, PROGESTERONE, 
ESTRADIOL CONCENTRATION (CON’T) 
 
mare tx/age d of ov d of tx LH P E PG 
MM  2 6 12.9 3.0 32  
MM  3 7 9.6 6.2 39  
MM  4 8 4.5 7.6 29  
Mandy c/11 -8 -5 3.5 2.6 31 PG 
Mandy  -7 -4 2.5 0.7 30  
Mandy  -6 -3 2.8 0.5 28  
Mandy  -5 -2 5.0 0.5 35  
Mandy  -4 -1 6.1 0.3 30  
Mandy  -3 0 7.5 0.7 38  
Mandy  -2 1 8.5 0.9 43  
Mandy  -1 2 9.6 1.0 48  
Mandy  0 3 11.6 1.3 48  
Mandy  1 4 9.5 1.4 40  
Mandy  2 5 10.8 3.9 37  
Mandy  3 6 11.5 7.5 34  
Mandy  4 7 6.1 11.4 32  
MariaFox tx/3 -12 -5 . 0.05 0 PG 
MariaFox  -11 -4 0 0.02 0  
MariaFox  -10 -3 0 0.07 0  
MariaFox  -9 -2 4.0 0.3 0  
MariaFox  -8 -1 0.4 0.03 0  
MariaFox  -7 0 0.8 0.05 0  
MariaFox  -6 1 4.0 0.4 0  
MariaFox  -5 2 4.0 0.6 0  
MariaFox  -4 3 4.0 1.0 0  
MariaFox  -3 4 1.8 0.1 2  
MariaFox  -2 5 1.9 0 4  
MariaFox  -1 6 5.1 0.02 4  
MariaFox  0 7 5.0 0.3 6  
MariaFox  1 8 4.7 1.1 7  
MariaFox  2 9 2.7 2.8 12  
MariaFox  3 10 1.0 3.4 7  
MariaFox  4 11 1.9 5.0 4  
Mercury c/4 -8 -5 7.1 0.1 6 PG 
Mercury  -7 -4 9.8 0.09 4  
Mercury  -6 -3 12.8 0.05 5  
Mercury  -5 -2 16.5 0.08 7  
Mercury  -4 -1 15.8 0.05 9  
Mercury  -3 0 16.9 0.8 11  
Mercury  -2 1 20 1.9 11  
Mercury  -1 2 17.2 2.8 11  
Mercury  0 3 13.7 5.0 7  
Mercury  1 4 18.4 6.9 10  
Mercury  2 5 7.1 8.2 6  
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RAW DATA FOR DAYS UNTIL OVULATION, LH, PROGESTERONE, 
ESTRADIOL CONCENTRATION (CON’T) 
 
mare tx/age d of ov d of tx LH P E PG 
Mercury  3 6 7.2 10.9 10  
Merrily c/5 -8 -5 1.2 7.7 317 PG 
Merrily  -7 -4 0.4 7.6 375  
Merrily  -6 -3 0.8 10.9 430  
Merrily  -5 -2 1.9 9.3 389  
Merrily  -4 -1 1.4 0.9 444  
Merrily  -3 0 3.1 0.2 276  
Merrily  -2 1 5.6 0.1 374  
Merrily  -1 2 8.6 0 390  
Merrily  0 3 10.7 0 352  
Merrily  1 4 13.7 0.7 304  
Merrily  2 5 13 2.8 261  
Merrily  3 6 10.4 5.0 265  
Merrily  4 7 9.2 5.9 259  
MsOakly c/3 -6 -5 2.1 2.2 9 NP 
MsOakly  -5 -4 1.8 0.3 8  
MsOakly  -4 -3 5.5 0.1 6  
MsOakly  -3 -2 6.3 0.2 8  
MsOakly  -2 -1 7.4 0.07 12  
MsOakly  -1 0 10 0.04 10  
MsOakly  0 1 15 0.1 8  
MsOakly  1 2 17.8 1.1 8  
MsOakly  2 3 18.1 3.2 7  
MsOakly  3 4 17.3 3.6 7  
NBM tx/3 -10 -5 2.2 0.3 6 PG 
NBM  -9 -4 2.0 0.1 10  
NBM  -8 -3 1.5 0 7  
NBM  -7 -2 3.0 0.02 7  
NBM  -6 -1 1.8 0 10  
NBM  -5 0 2.3 0 16  
NBM  -4 1 0.9 0.04 18  
NBM  -3 2 1.4 0 17  
NBM  -2 3 3.6 0 27  
NBM  -1 4 5.1 0 30  
NBM  0 5 6.9 0.03 36  
NBM  1 6 7.5 0.9 33  
NBM  2 7 4.9 3.0 19  
NBM  3 8 2.2 5.3 17  
NBM  4 9 6.3 7.0 15  
NuEnt c/3 -6 -4 2.3 0.06 5 PG 
NuEnt  -5 -3 2.3 0.07 8  
NuEnt  -4 -2 . . .  
NuEnt  -3 -1 . . .  
NuEnt  -2 0 5.5 0.03 23  
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RAW DATA FOR DAYS UNTIL OVULATION, LH, PROGESTERONE, 
ESTRADIOL CONCENTRATION (CON’T) 
 
mare tx/age d of ov d of tx LH P E PG 
NuEnt  -1 1 10.6 0.09 19  
NuEnt  0 2 11.2 0.4 23  
NuEnt  1 3 13.0 2.0 20  
NuEnt  2 4 5.3 4.7 15  
NuEnt  3 5 3.5 8.8 11  
NuEnt  4 6 0.9 9.5 12  
NNN tx/4 -17 -5 0.9 0.04 611 PG 
NNN  -16 -4 1.8 0 573  
NNN  -15 -3 1.5 0 541  
NNN  -14 -2 1.9 0 504  
NNN  -13 -1 1.4 0 643  
NNN  -12 0 1.6 0 639  
NNN  -11 1 2.9 0 617  
NNN  -10 2 4.5 0 551  
NNN  -9 3 3.4 0.03 502  
NNN  -8 4 4.0 0 487  
NNN  -7 5 3.8 0 442  
NNN  -6 6 3.7 0.8 437  
NNN  -5 7 2.2 0.02 420  
NNN  -4 8 3.0 0 399  
NNN  -3 9 2.4 0 422  
NNN  -2 10 3.4 0 438  
NNN  -1 11 4.5 0 308  
NNN  0 12 5.8 0.2 377  
NNN  1 13 7.8 1.9 344  
NNN  2 14 7.5 4.7 314  
NNN  3 15 5.6 7.8 287  
NNN  4 16 3.5 10 297  
NuRey c/4 -8 -5 4.0 0.1 698 PG 
NuRey  -7 -4 2.2 0 627  
NuRey  -6 -3 3.0 0.5 749  
NuRey  -5 -2 2.2 0.1 638  
NuRey  -4 -1 2.2 0.1 619  
NuRey  -3 0 2.8 0 522  
NuRey  -2 1 3.2 0.2 603  
NuRey  -1 2 5.7 0 480  
NuRey  0 3 6.3 0.05 443  
NuRey  1 4 8.2 0.9 472  
NuRey  2 5 7.7 2.6 429  
NuRey  3 6 6.7 4.2 406  
NuRey  4 7 . 5.0 408  
PCPuff tx/4 -7 -5 0.9 0.06 1720 PG 
PCPuff  -6 -4 0.4 0.08 1518  
PCPuff  -5 -3 0.5 0.1 1243  
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RAW DATA FOR DAYS UNTIL OVULATION, LH, PROGESTERONE, 
ESTRADIOL CONCENTRATION (CON’T) 
 
mare tx/age d of ov d of tx LH P E PG 
PCPuff  -4 -2 1.1 0.02 1310  
PCPuff  -3 -1 1.9 0.1 1268  
PCPuff  -2 0 1.9 0.02 1346  
PCPuff  -1 1 2.1 0 1373  
PCPuff  0 2 1.9 0 1188  
PCPuff  1 3 3.2 0.2 1170  
PCPuff  2 4 2.8 1.3 1139  
PCPuff  3 5 2.9 2.4 997  
PCPuff  4 6 3.6 4.7 1000  
PCPuff  5 7 2.9 4.8 972  
Polly c/23 -8 -5 1.4 14.4 18 NP 
Polly  -7 -4 4.5 2.9 23  
Polly  -6 -3 3.5 0.5 23  
Polly  -5 -2 3.3 0.1 21  
Polly  -4 -1 3.5 0.1 31  
Polly  -3 0 6.5 0.1 32  
Polly  -2 1 8.9 0.1 45  
Polly  -1 2 10.9 0.09 37  
Polly  0 3 13.0 0.07 33  
Polly  1 4 12.0 1.1 23  
Polly  2 5 13.3 2.5 20  
Polly  3 6 10.3 5.6 24  
Skippy c/6 -5 -5 7.7 0.2 8 PG 
Skippy  -4 -4 6.4 0.1 5  
Skippy  -3 -3 9.2 0.07 4  
Skippy  -2 -2 9.3 0.04 7  
Skippy  -1 -1 10.4 0.04 9  
Skippy  0 0 12.6 0.04 6  
Skippy  1 1 15.2 0.4 4  
Skippy  2 2 16.5 1.7 4  
Skippy  3 3 20.2 3.1 3  
Skippy  4 4 16.2 3.7 4  
SnipaBar tx/5 -9 -5 1.8 0.05 8 PG 
SnipaBar  -8 -4 2.2 0 5  
SnipaBar  -7 -3 3.5 0 6  
SnipaBar  -6 -2 3.3 0 7  
SnipaBar  -5 -1 3.2 0 8  
SnipaBar  -4 0 3.5 0 15  
SnipaBar  -3 1 3.4 0 17  
SnipaBar  -2 2 3.9 0.02 29  
SnipaBar  -1 3 6.0 0 27  
SnipaBar  0 4 7.5 0.1 32  
SnipaBar  1 5 9.2 1.1 23  
SnipaBar  2 6 5.6 2.9 21  
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RAW DATA FOR DAYS UNTIL OVULATION, LH, PROGESTERONE, 
ESTRADIOL CONCENTRATION (CON’T) 
 
mare tx/age d of ov d of tx LH P E PG 
SnipaBar  3 7 4.2 4.9 19  
SnipaBar  4 8 3.3 6.7 14  
SnipaBar  5 9 5.7 8.6 16  
Sparticus tx/18 -9 -5 5.9 1.5 36 PG 
Sparticus  -8 -4 6.2 2.0 36  
Sparticus  -7 -3 5.5 3.1 24  
Sparticus  -6 -2 5.0 2.8 28  
Sparticus  -5 -1 3.0 2.8 34  
Sparticus  -4 0 3.0 3.1 28  
Sparticus  -3 1 5.0 1.6 26  
Sparticus  -2 2 5.4 0.3 33  
Sparticus  -1 3 5.8 0.04 27  
Sparticus  0 4 9.2 0.09 32  
Sparticus  1 5 9.1 0.5 18  
Sparticus  2 6 10 1.6 21  
Sparticus  3 7 8.1 2.7 22  
Starlet c/3 -10 -5 0.5 0 0 PG 
Starlet  -9 -4 0.7 0 0  
Starlet  -8 -3 1.0 0 0  
Starlet  -7 -2 0.9 0 0  
Starlet  -6 -1 1.0 0 0  
Starlet  -5 0 1.8 0 0  
Starlet  -4 1 1.7 0 4  
Starlet  -3 2 2.4 0 8  
Starlet  -2 3 2.2 0 13  
Starlet  -1 4 3.2 0 19  
Starlet  0 5 5.7 0 21  
Starlet  1 6 4.7 0.1 20  
Starlet  2 7 5.3 1.9 15  
Starlet  3 8 1.0 3.7 11  
Starlet  4 9 2.8 7.7 9  
ThatsFoxy tx/3 -19 -5 1.1 0.06 0 PG 
ThatsFoxy  -18 -4 1.4 0 0  
ThatsFoxy  -17 -3 1.2 0.02 0  
ThatsFoxy  -16 -2 1.3 0.04 0  
ThatsFoxy  -15 -1 1.1 0 1  
ThatsFoxy  -14 0 1.0 0.05 9  
ThatsFoxy  -13 1 0.9 0 5  
ThatsFoxy  -12 2 2.9 0.08 3  
ThatsFoxy  -11 3 3.4 0 1  
ThatsFoxy  -10 4 3.3 0.05 3  
ThatsFoxy  -9 5 3.0 0 2  
ThatsFoxy  -8 6 6.5 0 2  
ThatsFoxy  -7 7 4.1 0 2  
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RAW DATA FOR DAYS UNTIL OVULATION, LH, PROGESTERONE, 
ESTRADIOL CONCENTRATION (CON’T) 
 
mare tx/age d of ov d of tx LH P E PG 
ThatsFoxy  -6 8 4.3 0.02 6  
ThatsFoxy  -5 9 2.9 0 12  
ThatsFoxy  -4 10 2.8 0 8  
ThatsFoxy  -3 11 2.8 0 25  
ThatsFoxy  -2 12 4.3 0 32  
ThatsFoxy  -1 13 5.2 0 29  
ThatsFoxy  0 14 6.3 0.4 24  
ThatsFoxy  1 15 4.7 2.3 22  
ThatsFoxy  2 16 2.0 5.1 21  
ThatsFoxy  3 17 1.9 7.2 16  
ThatsFoxy  4 18 5.6 9.3 16  
ThatsFoxy  5 19 10.8 10.4 11  
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RAW DATA FOR SIZE OF FOLLICLE AT OVULATION 
 
mare tx Follicle (mm) 
Ashley tx 46 
Babe tx 48 
Binky tx 50 
CandyBar c 52 
CC tx 46 
Diane c 57 
Dixie c 41 
FoxyLady c 41 
Lady tx 52 
MM tx 48 
Mandy c 45 
MariaFox tx 43 
Mercury c 47 
Merrily c 48 
MsOakly c 37 
NBM tx 42 
NuEnt c 45 
NNN tx 50 
NuRey c 45 
PCPuff tx 40 
Polly c 40 
Skippy c 35 
SnipaBar tx 47 
Sparticus tx 38 
Starlet c 49 
ThatsFoxy tx 45 
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ANOVA TABLES FOR DAYS TO OVULATION 
 
Number of Days to Ovulation 
 
Dependent Varible: dtov     
Source DF  Sum of Squares Mean Square F value Pr > F 
Model 25  248.7788465 9.9511538 . . 
Error 0  0.00000000 .   
Corrected Total 25  248.7788462    
  R-Square Coeff Var Root MSE Dtov Mean  
  1.000000 . . 4.634615  
       
Source DF  Type 1 SS Mean Square F value Pr > F 
trt 1  57.0096154 57.0096154 . . 
horse (trt) 24  191.7692308 7.9903846 . . 
       
Source DF  Type III SS Mean Square F value Pr > F 
trt  1  57.0096154 57.0096154 . . 
horse (trt) 24  191.7692308 7.99003846 . . 
       
Tests of Hypotheses Using the Type III MS for horse (trt) as an Error Term 
Source   Type III SS Mean Square F value Pr > F 
trt 1  57.0096154 57.0096154 7.13 0.0134 
horse (trt) 24  191.7692308 7.9903846 1.0 0.5000 
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ANOVA TABLES FOR SIZE OF FOLLICLE AT OVULATION 
 
Size of Follicle before Ovulation 
 
Dependent Varible: follicle     
Source DF  Sum of Squares Mean Square F value Pr > F 
Model 25  651.1153846 26.0446154 . . 
Error 0  0.00000000 .   
Corrected Total 25  651.1153846    
  R-Square Coeff Var Root MSE follicl Mean  
  1.000000 . . 45.26923  
       
Source DF  Type 1 SS Mean Square F value Pr > F 
trt 1  6.5000000 6.5000000 . . 
horse (trt) 24  644.6153846 26.8589744 . . 
       
Source DF  Type III SS Mean Square F value Pr > F 
trt  1  6.5000000 6.5000000 . . 
horse (trt) 24  644.6153846 26.8589744 . . 
       
Tests of Hypotheses Using the Type III MS for horse (trt) as an Error Term 
Source   Type III SS Mean Square F value Pr > F 
trt 1  6.5000000 6.5000000 0.24 0.6272 
horse (trt) 24  644.6153846 26.8589744 1.00 0.5000 
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ANOVA TABLES FOR LH CONCENTRATION 
 
LH Concentration with Day 0 as Ovulation 
 
Dependent Varible: LH     
Source DF  Sum of Squares Mean Square F value Pr > F 
Model 67  4484.982447 66.940037 15.62 <.0001 
Error 290  1242.542609 4.284630   
Corrected 
Total 
357  5727.525056    
  R-Square Coeff Var Root MSE LH Mean  
  0.783058 39.59163 2.069935 5.228212  
       
Source DF  Type 1 SS Mean Square F value Pr > F 
trt 1  610.454742 610.454742 142.48 <.0001 
horse (trt) 24  2231.142907 92.964288 21.70 <.0001 
day 24  1486.346156 61.931090 14.45 <.0001 
trt*day 18  157.038642 8.724369 2.04 0.0083 
       
Source DF  Type III SS Mean Square F value Pr > F 
trt  1  103.783707 103.783707 24.22 <.0001 
horse (trt) 24  1941.386862 80.891119 18.88 <.0001 
day 24  1536.927788 64.038658 14.95 <.0001 
trt*day 18  157.038642 8.724369 2.04 0.0083 
       
Tests of Hypotheses Using the Type III MS for horse (trt) as an Error Term 
Source   Type III SS Mean Square F value Pr > F 
trt 1  103.7837074 103.7837074 1.28 0.2685 
trt*day 18  157.0386419 8.7243690 0.11 1.0000 
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ANOVA TABLES FOR P CONCENTRATION 
 
Progesterone Concentration with Day 0 as Ovulation 
 
Dependent Varible: P     
Source DF  Sum of Squares Mean Square F value Pr > F 
Model 67  2070.381761 30.901220 5.52 <.0001 
Error 294  1645.2677623 5.596148   
Corrected 
Total 
361  3715.649385    
  R-Square Coeff Var Root MSE P Mean  
  0.557206 123.9781 2.365618 1.908094  
       
Source DF  Type 1 SS Mean Square F value Pr > F 
trt 1  12.800105 12.800105 2.29 0.1315 
horse (trt) 24  364.075304 15.169804 2.71 <.0001 
day 24  1651.896295 68.829012 12.30 <.0001 
trt*day 18  41.610057 2.311670 0.41 0.9847 
       
Source DF  Type III SS Mean Square F value Pr > F 
trt  1  6.080700 6.080700 1.09 0.2981 
horse (trt) 24  419.456075 17.477336 3.12 <.0001 
day 24  1609.232593 67.051358 11.98 <.0001 
trt*day 18  41.610057 2.311670 0.41 0.9847 
       
Tests of Hypotheses Using the Type III MS for horse (trt) as an Error Term 
Source   Type III SS Mean Square F value Pr > F 
trt 1  6.08069969 6.08069969 0.35 0.5608 
trt*day 18  41.61005722 2.31166985 0.13 1.0000 
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ANOVA TABLES FOR E CONCENTRATION 
 
Estradiol Concentration with Day 0 as Ovulation 
 
Dependent Varible: E     
Source DF  Sum of Squares Mean Square F value Pr > F 
Model 67  25575320.37 381721.20 126.62 <.0001 
Error 295  886291.70 3014.60   
Corrected 
Total 
361  26461612.07    
  R-Square Coeff Var Root MSE E Mean  
  0.966507 46.42671 54.90535 118.2624  
       
Source DF  Type 1 SS Mean Square F value Pr > F 
trt 1  341580.57 341580.57 113.31 <.0001 
horse (trt) 24  25071433.42 1044643.06 346.53 <.0001 
day 24  138661.44 5777.56 1.92 0.0070 
trt*day 18  23644.94 1313.61 0.44 0.9794 
       
Source DF  Type III SS Mean Square F value Pr > F 
trt  1  196362.04 196362.04 65.14 <.0001 
horse (trt) 24  24530438.19 1022101.59 339.05 <.0001 
day 24  108539.07 4522.46 1.50 0.0653 
trt*day 18  23644.94 1313.61 0.44 0.9794 
       
Tests of Hypotheses Using the Type III MS for horse (trt) as an Error Term 
Source   Type III SS Mean Square F value Pr > F 
trt 1  196362.0428 196362.0428 0.19 0.6868 
trt*day 18  23644.9406 1313.6078 0.00 1.0000 
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ANOVA TABLES FOR LH CONCENTRATION 
 
LH Concentration with Day 0 as Day of Treatment 
 
Dependent Varible: LH     
Source DF  Sum of Squares Mean Square F value Pr > F 
Model 66  4483.395983 67.930242 14.93 <.0001 
Error 291  1324.467816 4.551436   
Corrected 
Total 
357  5807.863799    
  R-Square Coeff Var Root MSE LH Mean  
  0.771953 41.10660 2.133409 5.189944  
       
Source DF  Type 1 SS Mean Square F value Pr > F 
trt 1  642.486122 642.486122 141.16 <.0001 
horse (trt) 24  2282.844645 95.118527 20.90 <.0001 
day 24  1294.957130 53.956547 11.85 <.0001 
trt*day 17  263.108086 15.476946 3.40 <.0001 
       
Source DF  Type III SS Mean Square F value Pr > F 
trt  1  351.502927 351.502927 77.23 <.0001 
horse (trt) 24  2533.260802 105.5522533 23.19 <.0001 
day 24  1282.950317 53.456263 11.74 <.0001 
trt*day 17  263.108086 15.476946 3.40 <.0001 
       
Tests of Hypotheses Using the Type III MS for horse (trt) as an Error Term 
Source   Type III SS Mean Square F value Pr > F 
trt 1  351.5029267 351.5029267 3.33 0.0805 
trt*day 17  263.1080855 15.4769462 0.15 0.9999 
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ANOVA TABLES FOR P CONCENTRATION 
 
Progesterone Concentration with Day 0 as Day of Treatment 
 
Dependent Varible: P     
Source DF  Sum of Squares Mean Square F value Pr > F 
Model 66  1735.735661 26.299025 3.9 <.0001 
Error 295  1987.066343 6.735818   
Corrected 
Total 
361  3722.802004    
  R-Square Coeff Var Root MSE P Mean  
  0.466244 136.4721 2.595345 1.901740  
       
Source DF  Type 1 SS Mean Square F value Pr > F 
trt 1  13.577079 13.577079 2.02 0.1567 
horse (trt) 24  368.248361 15.343682 2.28 0.0008 
day 24  1113.355798 46.389825 6.89 <.0001 
trt*day 17  240.554423 14.150260 2.10 0.0071 
       
Source DF  Type III SS Mean Square F value Pr > F 
trt  1  172.585042 172.585042 25.62 <.0001 
horse (trt) 24  588.729404 24.530392 3.64 <.0001 
day 24  1158.985375 48.291057 7.17 <.0001 
trt*day 17  240.554423 14.150260 2.10 0.0071 
       
Tests of Hypotheses Using the Type III MS for horse (trt) as an Error Term 
Source   Type III SS Mean Square F value Pr > F 
trt 1  172.5850420 172.5850420 7.04 0.0739 
trt*day 17  240.5544231 14.1502602 0.58 0.8772 
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ANOVA TABLES FOR E CONCENTRATION 
 
Estradiol Concentration with Day 0 as Day of Treatment 
 
Dependent Varible: E     
Source DF  Sum of Squares Mean Square F value Pr > F 
Model 66  25564153.35 387335.66 127.39 <.0001 
Error 295  896987.66 3040.64   
Corrected 
Total 
361  26461141.01    
  R-Square Coeff Var Root MSE E Mean  
  0.966102 46.62460 55.14196 118.2680  
       
Source DF  Type 1 SS Mean Square F value Pr > F 
trt 1  341689.32 341689.32 112.37 <.0001 
horse (trt) 24  25070862.66 1044619.28 343.55 <.0001 
day 24  128573.38 5357.22 1.76 0.0168 
trt*day 17  23027.99 1354.59 0.45 0.9732 
       
Source DF  Type III SS Mean Square F value Pr > F 
trt  1  172279.45 172279.45 56.66 <.0001 
horse (trt) 24  24827702.89 1034487.62 340.22 <.0001 
day 24  119726.91 4988.62 1.64 <.0001 
trt*day 17  23027.99 1354.59 0.45 0.0071 
       
Tests of Hypotheses Using the Type III MS for horse (trt) as an Error Term 
Source   Type III SS Mean Square F value Pr > F 
trt 1  172279.4518 172279.4518 0.17 0.6868 
trt*day 17  23027.9916 1354.5877 0.00 1.0000 
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CHI-SQUARE ANALYSIS OF PREGNANCY RATES 
 
Treatment Not Pregnant Pregnant Total Bred 
Control 2 10 13 
Treated 3 11 13 
Total 5 21 26 
 
 
  ƒe = (Row Total) (Column Total)/ (Grand Total) 
 
   
Treatment Not Pregnant Pregnant 
Control 2.5 10.5 
Treated 2.5 10.5 
 
   
ƒ0 ƒe ƒ0 - ƒe (ƒ0 - ƒe)2 (ƒ0 - ƒe)2 / ƒe 
2 2.5 -0.5 .25 0.1 
11 10.5 .5 .25 0.023 
3 2.5 -0.5 .25 0.1 
10 10.5 .5 .25 0.023 
 
 
  X2 = ∑ (ƒ0 - ƒe)2 / ƒe  
 
  X2 = 0.246 
 
  Critical Value = 3.841 
 
If computed (0.246) < Critical Value then accept null hypothesis 
concluding that pregnancy rates are the same. 
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